Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

8.62

Margin Of Safety %

48

Put/Call OI Ratio

0.04

EPS Next Q Diff

-0.35

EPS Last/This Y

-0.17

EPS This/Next Y

0.1

Price

2.97

Target Price

4.33

Analyst Recom

3

Performance Q

3.12

Relative Volume

0.94

Beta

1.09

Ticker: PBYI




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19PBYI2.80.080.003154
2024-12-20PBYI2.760.090.293056
2024-12-23PBYI2.810.040.001164
2024-12-24PBYI3.150.030.131574
2024-12-26PBYI3.160.030.161649
2024-12-27PBYI3.080.040.031708
2024-12-30PBYI3.130.040.001967
2024-12-31PBYI3.050.040.002034
2025-01-02PBYI3.120.040.002041
2025-01-03PBYI2.950.040.052040
2025-01-06PBYI3.550.040.002050
2025-01-07PBYI3.730.030.132173
2025-01-08PBYI3.550.020.002282
2025-01-09PBYI3.550.020.002282
2025-01-10PBYI3.320.020.242360
2025-01-13PBYI3.090.030.002342
2025-01-14PBYI3.080.030.832367
2025-01-15PBYI3.060.040.002414
2025-01-16PBYI3.020.040.532435
2025-01-17PBYI2.970.040.202460
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19PBYI2.78-54.8- 0.50
2024-12-20PBYI2.76-54.8- 0.50
2024-12-23PBYI2.81-54.8- 0.50
2024-12-24PBYI3.02-54.8- 0.50
2024-12-26PBYI3.15-54.8- 0.50
2024-12-27PBYI3.08-54.8- 0.50
2024-12-30PBYI3.12-54.8- 0.50
2024-12-31PBYI3.05-54.8- 0.50
2025-01-02PBYI3.12-54.8- 0.50
2025-01-03PBYI2.96-54.8- 0.50
2025-01-06PBYI3.55-54.8- 0.50
2025-01-07PBYI3.74-54.8- 0.50
2025-01-08PBYI3.55-54.8- 0.50
2025-01-09PBYI3.55-54.8- 0.50
2025-01-10PBYI3.32-54.8- 0.50
2025-01-13PBYI3.08-54.8- 0.50
2025-01-14PBYI3.08-54.8- 0.50
2025-01-15PBYI3.07-54.8- 0.50
2025-01-16PBYI3.02-54.8- 0.50
2025-01-17PBYI2.97-54.8- 0.50
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19PBYI-0.63-3.888.05
2024-12-20PBYI-0.63-3.888.05
2024-12-23PBYI-0.64-3.878.05
2024-12-24PBYI-0.64-3.878.05
2024-12-26PBYI-0.59-3.878.34
2024-12-27PBYI-0.63-3.878.34
2024-12-30PBYI-0.64-3.818.34
2024-12-31PBYI-0.64-3.818.34
2025-01-02PBYI-0.65-3.818.34
2025-01-03PBYI-0.39-3.818.34
2025-01-06PBYI-0.87-3.898.34
2025-01-07PBYI-0.87-3.898.34
2025-01-08PBYI-0.82-3.898.34
2025-01-09PBYI-0.82-3.898.32
2025-01-10PBYI-0.82-3.898.32
2025-01-13PBYI-0.82-3.898.62
2025-01-14PBYI-0.82-3.898.62
2025-01-15PBYI-0.82-3.898.62
2025-01-16PBYI-0.82-3.898.62
2025-01-17PBYI-0.82-3.898.62
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.41

Avg. EPS Est. Current Quarter

0.14

Avg. EPS Est. Next Quarter

0.06

Insider Transactions

-0.82

Institutional Transactions

-3.89

Beta

1.09

Average Sales Estimate Current Quarter

52

Average Sales Estimate Next Quarter

47

Fair Value

4.4

Quality Score

91

Growth Score

40

Sentiment Score

5

Actual DrawDown %

80.2

Max Drawdown 5-Year %

-88.7

Target Price

4.33

P/E

6.26

Forward P/E

8.74

PEG

P/S

0.6

P/B

2.05

P/Free Cash Flow

4.33

EPS

0.47

Average EPS Est. Cur. Y​

0.5

EPS Next Y. (Est.)

0.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.54

Relative Volume

0.94

Return on Equity vs Sector %

13.6

Return on Equity vs Industry %

26.2

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.06

EBIT Estimation

Puma Biotechnology Inc
Sector: Healthcare
Industry: Biotechnology
Employees: 185
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
stock quote shares PBYI – Puma Biotechnology, Inc. Stock Price stock today
news today PBYI – Puma Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PBYI – Puma Biotechnology, Inc. yahoo finance google finance
stock history PBYI – Puma Biotechnology, Inc. invest stock market
stock prices PBYI premarket after hours
ticker PBYI fair value insiders trading